Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Natera's Signatera detects gastroesophageal cancer recurrence over seven months ahead of imaging in trial

By Public Technologies
  • Natera will present 20 abstracts at the European Society for Medical Oncology congress in Madrid, Spain, October 23-26, 2026.
  • In the phase III SAGITTARIUS colon cancer trial, Signatera results prompted treatment changes, predominantly toward less intensive therapy following negative results.
  • The ICONIC gastroesophageal cancer trial linked molecular residual disease clearance during preoperative therapy to lower recurrence risk and favorable pathological response.
  • Signatera Genome detected all evaluable recurrences during ICONIC surveillance, identifying recurrence earlier than standard imaging.
  • A metastatic breast cancer analysis found sustained negative results among most exceptional responders, supporting potential Signatera-guided reductions in treatment intensity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610181810BIZWIRE_USPR_____20261018_BW851261) on October 18, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.